Currently out of the existing stock ratings of Max Masucci, 12 are a HOLD (16.67%), 60 are a BUY (83.33%).

Max Masucci

Work Performance Price Targets & Ratings Chart

Analyst Max Masucci, currently employed carries an average stock price target met ratio of 45.21% that have a potential upside of 22.55% achieved within 104 days. Previously, Max Masucci worked at COWEN.

Max Masucci’s has documented 130 price targets and ratings displayed on 20 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on CTKB, Cytek Biosciences at 08-Nov-2023.

Wall Street Analyst Max Masucci

Analyst best performing recommendations are on BDSX (BIODESIX ).
The best stock recommendation documented was for BDSX (BIODESIX ) at 1/11/2021. The price target of $27 was fulfilled within 4 days with a profit of $4.45 (19.73%) receiving and performance score of 49.33.

Average potential price target upside

of $46.95 (111.31%) on NTRA (NATERA).
of $36.76 (9.98%) on ILMN (ILLUMINA).
of $10.85 (93.39%) on BLFS (BIOLIFE SOLUTIONS).

BDSX Biodesix GNMK GenMark Diagnostics ILMN Illumina NTRA Natera BLFS BioLife Solutions DMTK DermTech QTRX Quanterix Corp ISO IsoPlexis Corp MXCT MaxCyte NAUT Nautilus Biotechnology SMFR Sema4 Holdings Corp TKNO Alpha Teknova XGN Exagen GH Guardant Health HOLX Hologic PKI PerkinElmer EVO Evotec SE ADR BRKR Bruker CDXS Codexis CTKB Cytek Biosciences

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Kyle Mikson (CANACCORD)